An Open Label, Prospective, Randomized, Parallel, Multi-center, Multi-Arm, Comparative Study to Assess the Efficacy and Safety of Goviro Soft Gel Capsule as an adjuvant with Imunocin tablet and SOC in patients with Upper Respiratory Tract Infection

Gufic Biosciences Limited0 个研究点目标入组 66 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Male/female of Ã¢â?°Â¥18 and Ã¢â?°Â¤65 years of age
•2.Patient who can and willing to provide written Informed Consent
•3.Patient with at least 2 symptoms of URTI (Sneezing, Runny nose, nose block, sore throat, fever, fatigue) since last 48 hours
•4.Patient who can take medicines orally
•5.Female of childbearing potential must have a negative urine pregnancy test and be non-lactating at screening visit
•6.Patient/ patientÃ¢â?¬•s legally acceptable representative understands and can comply with clinical trial protocol requirements

•1.Patient Ã?â?? 18 or Ã?Æ? 65 years of age
•2.Pregnant and/or nursing woman
•3.Patient with clinical evidence of a lower respiratory tract infection, as determined by the Investigator at the time of screening
•4.Patient with anticipated need for hospitalization or emergency room care within 24 hours of screening
•5.Patient with any other clinically significant illness
•6.Patient with cases/ instances of severe vomiting which would affect oral administration of medicine
•7.Patient taking any medication or having an indication that might point to an increased risk, associated with study participation or study drug administration or may interfere with the interpretation of study results and in the judgment of the study personnel, would make the subject inappropriate for inclusion
•8.Patient who has participated in another trial with an investigational drug within 3 months prior to this trial.
•9.Patient with history of malignancy, Cardiovascular Disease (CVD), Stroke, etc.
•10.Patient with moderate to severe COVID 19 symptoms
•11.Patient with any other condition, which as per the investigator would jeopardize the outcome of the trial
•12.Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol

发起方